Bruker (BRKR) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $864.4M, up 16.4% year-over-year, with organic growth of 3.1% and CER growth of 15.7%, driven by strategic acquisitions and organic expansion.

• Non-GAAP EPS for Q3 2024 was $0.60, down 18.9% year-over-year; GAAP EPS was $0.27, with margins pressured by acquisition-related costs.

• Major acquisitions in 2024, including ELITech, NanoString, Chemspeed, and PhenomeX, expanded capabilities in diagnostics, spatial biology, and lab automation.

• Net income attributable to the company was $40.9M for Q3 2024, down 53.6% from Q3 2023, primarily due to higher costs and integration expenses.

• FY2024 guidance was lowered due to delayed recoveries in biopharma and China, with organic growth now expected at 3–4% and non-GAAP EPS at $2.36–$2.41.

Financial highlights

• Q3 2024 operating income was $68.1M (GAAP), down from $124.5M in Q3 2023; non-GAAP operating income was $129.1M, down 12.9%.

• Q3 2024 non-GAAP operating margin was 14.9%, down 510 bps year-over-year; non-GAAP gross margin was 51.2%, down 150 bps.

• First nine months 2024 revenue was $2.39B, up 13.1% year-over-year, with organic growth of 4.0%.

• Free cash flow for Q3 2024 was $5.8M, down from $17.2M a year ago, reflecting lower net income and acquisition-related expenses.

• Cash and cash equivalents at September 30, 2024, were $148.1M; total debt increased to $2.3B.

Outlook and guidance

• FY2024 revenue guidance is $3.34–$3.37B, up 12.5–13.5% year-over-year, with organic growth of 3–4% and non-GAAP EPS of $2.36–$2.41.

• Non-GAAP operating margin expected at ~15%, with >300 bps headwind from M&A.

• Further sequential margin improvements and double-digit CER revenue growth anticipated in Q4.

• Significant margin expansion and above-market organic growth targeted for 2025 as acquisitions are integrated.

• Cash and credit facilities are expected to be sufficient for operating and investing needs for at least the next twelve months.